This study is for people with a type of brain cancer called glioblastoma that has returned after treatment. The study tests a drug called Visudyne (also known as verteporfin) to see how safe it is and the best dose to use. Visudyne is usually used with light for eye diseases but here it’s used like chemotherapy to kill cancer cells.

In this study, patients will receive Visudyne through an IV for about 83 minutes each week. The study aims to find the highest dose patients can tolerate and see if the cancer stops growing. The study includes a follow-up period after treatment.

• The study lasts for 6 weeks per cycle, with weekly treatments, and can repeat cycles if needed.
• Patients need to have a specific mutation in their tumor to participate.
• Patients must agree to use birth control as the effects on pregnancy are unknown.

This study is important for understanding if Visudyne can help treat recurrent glioblastoma and what side effects it may cause. If you join, you'll be contributing to important research that might help others in the future.